Skip to main content

Call for papers - Hereditary cancer syndromes

Guest Editors

Daniele Fanale, PhD, University of Palermo, Italy
Mev Domínguez Valentin, PhD, Oslo University Hospital, Norway
Ling Zhang, MD, H Lee Moffitt Cancer Center and Research Institution, USA

Submission Status: Open   |   Submission Deadline: 22 February 2025

BMC Cancer is inviting submissions to its Collection on Hereditary cancer syndromes. This Collection seeks to emphasize the significance of understanding genetic predispositions to cancer and their implications for clinical care. We are interested in topics exploring the genetic underpinnings, clinical manifestations, and management strategies of various hereditary cancer syndromes. Additionally, we welcome submissions that delve into the impact of environmental factors, advancements in genetic testing, and psychosocial aspects of care within the realm of cancer-associated syndromes. By addressing these topics, the Collection aims to advance knowledge, improve risk assessment, and foster personalized approaches to cancer prevention and treatment for individuals with hereditary cancer predisposition.

Meet the Guest Editors

Back to top

Daniele Fanale, PhD, University of Palermo, Italy

Dr/Prof Daniele Fanale, PhD, Researcher in Medical Oncology, Biologist Executive at the “Sicilian Regional Center for the Prevention, Diagnosis and Treatment of Rare and Heredo-Familial Tumors” of the Section of Medical Oncology of University Hospital Policlinico “P. Giaccone” of Palermo (Italy). PhD in “Molecular and Cellular Oncopathology” at the University of Palermo (Italy) in 2010. In these years, he has been involved in projects of translational oncology research aimed at identifying new potential biomarkers in cancer for diagnostic, prognostic and predictive purposes. In this context, he has been concerned with the genetic counselling and molecular genetics of sporadic and heredo-familial tumors. For the past year, he has also been involved in the projects concerning the immuno-oncology in several solid tumors.

Mev Domínguez Valentin, PhD, Oslo University Hospital, Norway

Mev Domínguez-Valentin (MDV), PhD is a Project Group Leader in the Department of Tumor Biology of the Institute for Cancer Research from Oslo University Hospital (Norway). She is the Principal Investigator of the largest database in Lynch Syndrome (PLSD) that aims to facilitate personalized precision medicine for Lynch Syndrome. 

MDV has had extensive mobility throughout her career, with activity across many countries, and even two continents. Her main research areas include Lynch Syndrome (LS) and the large prospective observational studies that have recently increased understanding of the effectiveness of colonoscopic surveillance and the heterogeneity of cancer risk between genotypes. Also, the use of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing, to gain information on to which degree other genes may have been causative for cancer in the patients and their relatives, and to be informed on how such genes were deranged to discriminate between normal and disease-causing variants. MDV is also interested in unravelling the challenges of implementing the advances in diagnosis of hereditary cancer susceptibility and applying these insights to clinical practice in Latin America. In addition, MDV has established national and international collaborations in LS that have been crucial, especially in generating knowledge about mismatch repair genes variant classification and sharing of genetic practices within the region. MDV pursues her interest in the genetic epidemiology of hereditary cancers in low-resource setting in Peru. At educational and mentoring level, MDV is co-founder of the Research Experience for Peruvian Undergraduates Program (REPU), active mentor of the international mentoring program in Peru and actively promotes the research of Peruvian scientists in Europe (SINAPSIS).

MDV is board member of the European Hereditary Tumor Group (EHTG), Ambassador at the North American Group (CGA) and Scientific advisor of the Latin America Group of the Hereditary Tumors (LA-GETH).

Ling Zhang, MD, H Lee Moffitt Cancer Center and Research Institution, USA

Dr Ling Zhang has engaged in diagnosis and research of cancers, especially hematologic malignancies for the past two decades and would like to share her personal experiences in the application of molecular markers in diagnosis of disease, prediction of disease prognosis, and potential treatment to try to guide authors to contribute advanced research results and reviews in the Collection for best clinical practice and patience care.

About the Collection

Hereditary cancer syndromes, also referred to as cancer associated syndromes or familial cancer syndromes, encompass a group of genetic disorders characterized by inherited mutations predisposing individuals to certain types of cancer. These syndromes pose significant challenges in oncology due to their complex genetic underpinnings, variable penetrance, and diverse clinical presentations. Understanding the molecular mechanisms underlying these syndromes is essential for improving risk assessment, early detection, and management strategies in affected individuals and their families. Examples include: Hereditary Breast and Ovarian Cancer Syndrome (HBOC), Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer or HNPCC), Li-Fraumeni Syndrome, Familial Adenomatous Polyposis (FAP), Hereditary Diffuse Gastric Cancer Syndrome.

In light of these challenges, BMC Cancer is launching this Collection on Hereditary cancer syndromes, exploring the genetic, clinical, and therapeutic dimensions of inherited cancer predisposition. Articles of interest include:

  • Genetic and molecular characterization of cancer-associated syndromes
  • Identification and functional analysis of novel cancer predisposition genes
  • Epidemiology and population studies of hereditary cancer syndromes
  • Clinical manifestations, diagnostic criteria, and screening guidelines for cancer-associated syndromes
  • Management strategies for individuals with hereditary cancer predisposition, including surveillance, risk-reducing interventions, and personalized treatment approaches
  • Psychosocial aspects of hereditary cancer syndromes, including genetic counseling, patient education, and family communication
  • Challenges and opportunities in genetic testing, family counseling, and implementation of precision medicine approaches for cancer-associated syndromes
  • Impact of environmental factors, lifestyle interventions, and preventive measures on cancer risk and outcomes in individuals with hereditary cancer predisposition
  • Research articles and study protocols, especially ones that aim to established patient registries to advance clinical care and advocate for individuals with cancer-associated syndromes
  • Translational research and preclinical models for studying cancer-associated syndromes, including patient-derived xenografts, organoids, and genetically engineered mouse models
  • Novel therapeutic strategies, targeted agents, and immunotherapies for treating cancers associated with specific syndromes
  • Long-term outcomes, survivorship issues, and quality of life in individuals with hereditary cancer predisposition and their families

Image credit: © joy /

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Hereditary cancer syndromes" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.